Llicenciada en Biologia (2004) i doctora per la Universitat de Girona (2010). Actualment és professora agregada de l’àrea de Bioquímica i Biologia Molecular de la UdG i està vinculada al grup de recerca d’Enginyeria de Proteïnes de la mateixa universitat. Durant l’any 2016 va realitzar una estada de recerca al European Cancer Stem Cell Research Institute de la Universitat de Cardiff (UK). La seva recerca es basa principalment en l’estudi del mecanisme de citotoxicitat de ribonucleases i en el disseny de noves ribonucleases amb activitat antitumoral. Publicacions de recerca: The selectivity for tumor cells of nuclear-directed cytotoxic RNases is mediated by the nuclear /cytoplasmic distribution of p27KIP1. Molecules (2021) Strengths and challenges of secretory ribonucleases as antitumor agents. Pharmaceutics (2021) A versatile protein with selective antitumor activity. Current Medicinal Chemistry (2018) Construction of Highly Stable Cytotoxic Nuclear-Directed Ribonulceases. Molecules (2018) Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance. OncoTargets and Therapy (2018) A family of manganese complexes containing heterocyclic-based ligands with cytotoxic properties. Journal of Inorganic Biochemistry (2018) Insights into the mechanism of Apoptin's exquisitely selective anti-tumor action from atomic level characterization of its conformation and dynamics. Archives of Biochemistry and Biophysics (2017) A Truncated Apoptin Protein Variant Selectively Kills Cancer Cells. Investigational New Drugs (2017) Approaches to Endow Ribonucleases with Antitumor Activity: Lessons Learned from the Native Cytotoxic Ribonucleases. Anti-cancer Drugs - Nature, Synthesis and Cell (2016) Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of onconase. Oncotarget (2016) A nuclear-directed human pancreatic ribonuclease (PE5) targets the metabolic phenotype of cancer cells. Oncotarget (2016) Nucleus-targeted ribonucleases as antitumor drugs. Current Medicinal Chemistry (2013) A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines. Investigational New Drugs (2012) Generation of New Cytotoxic Human Ribonuclease Variants Directed to the Nucleus. Molecular Pharmaceutics (2012) A human ribonuclease induces apoptosis associated with p21WAF1/CIP1 induction and JNK inactivation. BMC Cancer (2011) Contribution of the C30/C75 disulfide bond to the biological properties of onconase. Biological Chemistry (2008) A cytotoxic ribonuclease variant with a discontinuous nuclear localization signal constituted by basic residues scattered over three areas of the molecule. Journal of Molecular Biology (2006)